Duke Early Phase Clinical Research combines clinical, analytical, and operational expertise to accelerate the availability of therapies, diagnostics, and medical devices to humans.
As part of the Duke Office of Clinical Research, the Early Phase team partners with pharmaceutical, biotech, medical device, government agencies, foundations, and academic centers to conduct a broad range of early phase studies.
Your Path to Proof
We are driven by innovation and public health impact. With 50+ experienced personnel in early phase clinical research, a state-of-the-art research unit, and robust data analytics, we offer our partners a different approach to early phase research, including:
- Thought leadership and scientific insight in early phase clinical research that leads to innovation
- Full-service capabilities and customized study design grounded in the reality of clinical care
- Access to healthy and diverse disease-specific patient populations
Duke Early Phase Clinical Research has the staff and resources to conduct a variety of studies, from proof-of-concept to first-in-human. We leverage the unique capabilities of an academic medical center, adaptive design methodologies, and access to specialized services to conduct healthy volunteer and POC studies. Explore our capabilities:
- Specialized Facilities and Technologies
- Rapid Recruitment
- Study Design
- Data Analytics
- DEPRU Service Center Rates
DEPRU Welcome Pack
- Table of Contents
- Welcome to DEPRU
- Overview of Services
- Contact List
- DEPRU Pharmacy Services
- Laboratory Services
- Nutrition Services
- Recruitment Services
- DEPRU House Rules Nov. 2020
- Pre-Initiation Checklist
- DEPRU Study Services Request Form
- Scheduling a Subject Visit
- New Schedule Request Form 8.29.2020
- Study Plan Template
- Frequently Asked Questions
- Participant Visitation Standard Operating Procedure
The role of study volunteers in clinical research is crucial in the advancement of medicine. Without volunteer participation, new ways to prevent, diagnose, and treat diseases cannot be achieved.
Here's what you need to know about participation.
If you are interested in being contacted for future research studies when it appears that you may be eligible based on the information you provide us, join our Research Volunteer Registry.
Our recruitment staff is available Monday-Friday to answer your questions. If you call outside these hours, leave a message, and your call will be returned.
Need to find us? Get driving directions here.
Lynn Jordan - Senior Project Manager and Clinical Laboratory Manager
Debra Freeman- Nurse Manager
Selected Study Publications
Study Publication Link. In this PK-PD study of a novel B cell depleting therapeutic administered to lupus and rheumatoid arthritis patients, we determined:
- The drug was well tolerated with pretreatment
- B cell depletion in this patient population was long-lasting
- The duration of B cell depletion was greater in patients with rheumatoid arthritis than systemic lupus erythematosus, suggesting higher doses may be required for patients with lupus
Study Publication Link. In this first-in-human SAD/MAD study of a small peptide beginning clinical development for acute brain injury, we found:
- No significant safety issues with the compound
- PK analysis revealed predictable PK properties without significant drug accumulation